DMD and Duchenne muscular dystrophy: In August 2020, the FDA granted accelerated approval to viltolarsen (Viltepso®) based on data demonstrating an increase in dystrophin production in DMD patients with mutations amenable to exon 53 skipping (FDA, 2020).